Henry Schein Inc (HSIC) Files Form 4 Insider Selling : James A. Harding Sells 10,302 Shares

Henry Schein Inc (HSIC): James A. Harding , SVP, Chief Technology Officer of Henry Schein Inc sold 10,302 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were sold at $172.60 per share for a total value of $1,778,125.25 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Peter M. Mccarthy (Pres., Global Animal Health) sold 1,158 shares at $171.75 per share price.On Mar 16, 2016, Lonnie Shoff (CEO, Global Strat Port Grp) sold 3,028 shares at $168.29 per share price.Also, On Mar 15, 2016, David Mckinley (President, Medical Group) sold 3,339 shares at $167.92 per share price.On Mar 15, 2016, Norman S Matthews (director) sold 5,335 shares at $167.76 per share price.

Henry Schein: On Monday, May 16, 2016 heightened volatility was witnessed in Henry Schein which led to swings in the share price. The shares opened for trading at $171.63 and hit $174.45 on the upside , eventually ending the session at $174.13, with a gain of 1.26% or 2.16 points. The heightened volatility saw the trading volume jump to 3,58,730 shares. The 52-week high of the share price is $174.75 and the company has a market cap of $14,290 M . The 52-week low of the share price is at $126.17.

Henry Schein Money Flow Index Chart

Company has been under the radar of several Street Analysts.Henry Schein is Reiterated by Barrington Research to Outperform and the brokerage firm has raised the Price Target to $ 188 from a previous price target of $182 .The Rating was issued on May 4, 2016.Henry Schein is Initiated by Credit Suisse to Neutral. The Rating was issued on Mar 16, 2016.Henry Schein is Upgraded by Barrington Research to Outperform and the brokerage firm has set the Price Target at $182. Earlier the firm had a rating of Mkt Perform on the company shares. The Rating was issued on Mar 1, 2016.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.